Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
Status:
Active, not recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed
by rituximab in patients with previously treated follicular lymphoma. The purpose of this
study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and
preliminary anti-tumour activity of Betalutin in combination with rituximab.